Through combining the clinicopathological data of ccRCC patients in TCGA-KIRC, it was found that the expression level of ZNF582 mRNA in T3/T4, Stage III/IV, G3/G4, N1 and M1 patients is significantly decreased than that in T1/T2, Stage I/II, G1/G2, N0 and M0 patients, respectively (Fig. S1C). This evidence concerns the gene ZNF582 and nonpapillary renal cell carcinoma.